BioNTech, which changed the course of the epidemic by developing the mRNA-based coronavirus vaccine, and Pfizer announced that the new vaccine, which is especially effective for the omicron variant, is ready and the trial process will begin. In a statement made by Pfizer manager Kathrin Jansen, he explained that it is necessary to stay vigilant against the virus and therefore they want the new vaccine to be ready for use as soon as possible.
Pfizer and BioNTech’s new vaccine effective against the omicron variant will be tested on three groups. According to the statements made, the first group will consist of people who have never been vaccinated. The second group will include people who have received two doses of the BioNTech vaccine. The third group will consist of people who have been vaccinated three doses so far. The experimental study will involve 1,420 adults.
Can the pandemic end with the new vaccine?
Pfizer and BioNTech did not provide detailed information about the new vaccine. Because nothing is known about the results to be achieved. However, this vaccine is promising for many scientists. Experts believe that a vaccine that focuses directly on omicron could end the pandemic. But here, too, there are some unclear situations. Although the dominant variant of recent periods is omicron, different variants such as delta can still be seen.
It should be noted that vaccine studies on the Omicron variant are not limited to Pfizer and BioNTech. So much so that Moderna is developing a new coronavirus vaccine focused on omicron. On the other hand; Johnson & Johnson, on the other hand, announced that it will start a new vaccine study if necessary. The coming days seem to be more decisive in terms of the course of the epidemic.
34107
